Results 21 to 30 of about 13,549 (163)

Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling

Scientific Reports
Cancer therapy-related cardiovascular toxicity (CTR-CVT) is now recognised as one of the leading causes of long-term morbidity and mortality in cancer patients.
Conagh Kelly, Dylan J. Kiltschewskij, Angeline J.W. Leong, Tatt Jhong Haw, Amanda J. Croft, Lohis Balachandran, Dongqing Chen, Danielle R. Bond, Heather J. Lee, Murray J. Cairns, Aaron L. Sverdlov, Doan T. M. Ngo   +11 more
doaj   +2 more sources

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma [PDF]

Клиническая онкогематология, 2019
Carfilzomib (Kyprolis®, Amgen), a second-generation proteasome inhibitor, is capable of covalent bonding and irreversible inhibition of the 20S proteasome chymotrypsin-like activity.
Sergei Vyacheslavovich Semochkin, G. N. Salogub, S. S. Bessmeltsev, K. D. Kaplanov   +3 more
doaj   +2 more sources

Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma [PDF]

Cardio-Oncology, 2018
Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM).
Eric H. Yang, Cynthia Courtney, Vinisha Garg, Michael G. Fradley, Gary J. Schiller   +4 more
doaj   +2 more sources

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

Blood and Lymphatic Cancer: Targets and Therapy, 2017
Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in ...
Bhutani D, Zonder JA
doaj   +1 more source

Pulmonary toxicity induced by carfilzomib: a case report and review of the literature

Journal of Medical Case Reports
Background Carfilzomib (Kyprolis™) is a second-generation proteasome inhibitor registered for the management of relapsed or refractory multiple myeloma. Drug safety profile includes hypertension, heart failure, and acute kidney failure.
Mateusz Ziarkiewicz, Aleksandra Zacny, Grzegorz Basak, Laretta Grabowska-Derlatka   +3 more
doaj   +2 more sources

Hypertension, smoking, and preexistence of multiple cardiac risk factors correlate with carfilzomib-induced cardiovascular adverse events in a racially diverse population

Frontiers in Cardiovascular Medicine, 2023
BackgroundUse of the proteasome inhibitor carfilzomib has become a standard of care in patients with relapsed/refractory multiple myeloma. An association between carfilzomib and cardiovascular adverse events has been well documented, but this had not ...
Stacey Doran, Manu Mysore, Seyed Ebrahim Kassaian, Ethan Kotloff, Farin Kamangar, Ashkan Emadi, Ashkan Emadi, Ashkan Emadi, Jummai Apata, Brian Barr   +9 more
doaj   +1 more source

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. [PDF]

PLoS ONE, 2013
Carfilzomib, the next generation of proteasome inhibitor, may increase osteoblast-related markers in patients with multiple myeloma, but the molecular mechanism of its effect on mesenchymal stem cell differentiation to osteoblasts remains unknown. Herein,
Bo Hu, Yu Chen, Saad Z Usmani, Shiqiao Ye, Wei Qiang, Xenofon Papanikolaou, Christoph J Heuck, Shmuel Yaccoby, Bart O Williams, Frits Van Rhee, Bart Barlogie, Joshua Epstein, Ya-Wei Qiang   +12 more
doaj   +1 more source

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

Frontiers in Oncology, 2021
BackgroundInfants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival.
Laurence C. Cheung, Laurence C. Cheung, Rebecca de Kraa, Joyce Oommen, Grace-Alyssa Chua, Sajla Singh, Anastasia M. Hughes, Emanuela Ferrari, Jette Ford, Sung K. Chiu, Ronald W. Stam, Ursula R. Kees, Sébastien Malinge, Rishi S. Kotecha, Rishi S. Kotecha, Rishi S. Kotecha   +15 more
doaj   +1 more source

Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer

EMBO Molecular Medicine, 2021
Impressive clinical benefit is seen in clinic with PD‐1 inhibitors on portion of cancer patients. Yet, there remains an urgent need to develop effective synergizers to expand their clinical application.
Qian Zhou, Jinxia Liang, Tong Yang, Jin Liu, Bo Li, Yingchang Li, Zhenzhen Fan, Weida Wang, Wensheng Chen, Sujing Yuan, Meng Xu, Qigui Xu, Zhidong Luan, Zhongjun Xia, Penghui Zhou, Yadong Huang, Liang Chen   +16 more
doaj   +1 more source

Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients

Frontiers in Cardiovascular Medicine, 2021
Background: Carfilzomib improves the prognosis of multiple myeloma (MM) patients but significantly increases cardiovascular toxicity. The timing and effect of Carfilzomib therapy on the left ventricular function is still under investigation. We sought to
Giulia Mingrone, Anna Astarita, Lorenzo Airale, Ilaria Maffei, Marco Cesareo, Teresa Crea, Giulia Bruno, Dario Leone, Eleonora Avenatti, Cinzia Catarinella, Marco Salvini, Giusy Cetani, Francesca Gay, Sara Bringhen, Franco Veglio, Fabrizio Vallelonga, Alberto Milan   +16 more
doaj   +1 more source